Literature DB >> 25367948

Insights into the mechanism of organ-specific cancer metastasis.

Mark A Rubin1.   

Abstract

SUMMARY: Lucas and colleagues nominate transmembrane serine protease type II (TMPRSS2) as an important player in the initiation of epithelial-mesenchymal transition (EMT) in prostate cancer. Cancer cells maintain androgen receptor-regulated cytoplasmic TMPRSS2 expression, which facilitates EMT invasion and metastasis in model systems through hepatocyte growth factor and c-MET signaling. In addition to providing a rationale for potentially targeting this organ-specific enabler of metastatic disease progression, this study also highlights the importance of understanding how organ/tissue-specific genes are co-opted in the context of cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25367948      PMCID: PMC4418487          DOI: 10.1158/2159-8290.CD-14-1075

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  12 in total

1.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

2.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

3.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Authors:  Jared M Lucas; Cynthia Heinlein; Tom Kim; Susana A Hernandez; Muzdah S Malik; Lawrence D True; Colm Morrissey; Eva Corey; Bruce Montgomery; Elahe Mostaghel; Nigel Clegg; Ilsa Coleman; Christopher M Brown; Eric L Schneider; Charles Craik; Julian A Simon; Antonio Bedalov; Peter S Nelson
Journal:  Cancer Discov       Date:  2014-08-13       Impact factor: 39.397

Review 4.  Common gene rearrangements in prostate cancer.

Authors:  Mark A Rubin; Christopher A Maher; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

5.  Delineation of prognostic biomarkers in prostate cancer.

Authors:  S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan
Journal:  Nature       Date:  2001-08-23       Impact factor: 49.962

6.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.

Authors:  B Lin; C Ferguson; J T White; S Wang; R Vessella; L D True; L Hood; P S Nelson
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.

Authors:  J M Lucas; L True; S Hawley; M Matsumura; C Morrissey; R Vessella; P S Nelson
Journal:  J Pathol       Date:  2008-06       Impact factor: 7.996

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Authors:  Christine Feig; James O Jones; Matthew Kraman; Richard J B Wells; Andrew Deonarine; Derek S Chan; Claire M Connell; Edward W Roberts; Qi Zhao; Otavia L Caballero; Sarah A Teichmann; Tobias Janowitz; Duncan I Jodrell; David A Tuveson; Douglas T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

View more
  4 in total

Review 1.  Melatonin: an inhibitor of breast cancer.

Authors:  Steven M Hill; Victoria P Belancio; Robert T Dauchy; Shulin Xiang; Samantha Brimer; Lulu Mao; Adam Hauch; Peter W Lundberg; Whitney Summers; Lin Yuan; Tripp Frasch; David E Blask
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

2.  TRIM37 promotes epithelial‑mesenchymal transition in colorectal cancer.

Authors:  Cheng-En Hu; Jun Gan
Journal:  Mol Med Rep       Date:  2017-01-16       Impact factor: 2.952

3.  MicroRNA‑34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel.

Authors:  Megumi Yanokura; Kouji Banno; Daisuke Aoki
Journal:  Int J Oncol       Date:  2020-09-23       Impact factor: 5.650

4.  Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.

Authors:  Rama Krishna Nimmakayala; Frank Leon; Satyanarayana Rachagani; Sanchita Rauth; Palanisamy Nallasamy; Saravanakumar Marimuthu; Gautam K Shailendra; Yashpal S Chhonker; Seema Chugh; Ramakanth Chirravuri; Rohitesh Gupta; Kavita Mallya; Dipakkumar R Prajapati; Subodh M Lele; Thomas C Caffrey; Jean L Grem; Paul M Grandgenett; Michael A Hollingsworth; Daryl J Murry; Surinder K Batra; Moorthy P Ponnusamy
Journal:  Oncogene       Date:  2020-10-27       Impact factor: 8.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.